Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Redner

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
PRAMEing a picture of differentiation therapy for AML?Robert L Redner
The Oncologist|February 4, 2010
Why doesn't imatinib cure chronic myeloid leukemia?Robert L Redner
Cancer Genetics and Cytogenetics|July 17, 2010
Cryptic insertion of PML-RARA into the 3p25 locus in an acute promyelocytic leukemia with t(3;17)(p25;q21)Anuja Chattopadhyay, Robert L Redner
Journal of Cellular Biochemistry|January 26, 2005
Leukemia fusion proteins and co-repressor complexes: changing paradigmsRobert L Redner, Johnson M Liu
Blood|July 9, 2010
Knee pain: ACL, MCL, or CML?Enrico M Novelli, Robert L Redner
International Journal of Hematology|January 4, 2021
The eyes have it: CNS leukemia presenting as optic neuritisKevin A Quann, Robert L Redner
Blood Reviews|January 30, 2015
An ATRActive future for differentiation therapy in AMLDaniel E Johnson, Robert L Redner
Leukemia & Lymphoma|March 21, 2015
NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNKAnuja Chattopadhyay, Irina Abecassis, Robert L Redner
Leukemia & Lymphoma|August 10, 2013
NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiationSheri L Pollock, Elizabeth A Rush, Robert L Redner
Journal of Clinical Apheresis|March 2, 2013
Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostimJay S Raval, Robert L Redner, Joseph E Kiss
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2013
PRAMEing a picture of differentiation therapy for AML?Robert L Redner
The Oncologist|February 4, 2010
Why doesn't imatinib cure chronic myeloid leukemia?Robert L Redner
Cancer Genetics and Cytogenetics|July 17, 2010
Cryptic insertion of PML-RARA into the 3p25 locus in an acute promyelocytic leukemia with t(3;17)(p25;q21)Anuja Chattopadhyay, Robert L Redner
Journal of Cellular Biochemistry|January 26, 2005
Leukemia fusion proteins and co-repressor complexes: changing paradigmsRobert L Redner, Johnson M Liu
Blood|July 9, 2010
Knee pain: ACL, MCL, or CML?Enrico M Novelli, Robert L Redner
International Journal of Hematology|January 4, 2021
The eyes have it: CNS leukemia presenting as optic neuritisKevin A Quann, Robert L Redner
Blood Reviews|January 30, 2015
An ATRActive future for differentiation therapy in AMLDaniel E Johnson, Robert L Redner
Leukemia & Lymphoma|March 21, 2015
NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNKAnuja Chattopadhyay, Irina Abecassis, Robert L Redner
Leukemia & Lymphoma|August 10, 2013
NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiationSheri L Pollock, Elizabeth A Rush, Robert L Redner
Journal of Clinical Apheresis|March 2, 2013
Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostimJay S Raval, Robert L Redner, Joseph E Kiss
Pageof 5